ID   HepaRG
AC   CVCL_9720
SY   Hepa-RG
DR   BTO; BTO:0005736
DR   EFO; EFO_0001186
DR   ChEMBL-Cells; CHEMBL4630773
DR   ChEMBL-Targets; CHEMBL4630781
DR   Cosmic; 2162524
DR   MetaboLights; MTBLS78
DR   Millipore; C103485
DR   PRIDE; PXD001107
DR   PRIDE; PXD004752
DR   PRIDE; PXD006267
DR   PRIDE; PXD010304
DR   PubChem_Cell_line; CVCL_9720
DR   Wikidata; Q54882834
RX   Patent=US7456018;
RX   PubMed=12432097;
RX   PubMed=17241619;
RX   PubMed=17393521;
RX   PubMed=20228232;
RX   PubMed=20645056;
RX   PubMed=21414303;
RX   PubMed=22568886;
RX   PubMed=22594799;
RX   PubMed=22643240;
RX   PubMed=22857383;
RX   PubMed=23887712;
RX   PubMed=26160117;
RX   PubMed=26694163;
RX   PubMed=27027780;
RX   PubMed=27169750;
RX   PubMed=27780834;
RX   PubMed=27975304;
RX   PubMed=28904299;
RX   PubMed=30795634;
RX   PubMed=31063779;
RX   PubMed=33441761;
WW   http://www.heparg.com/
WW   https://en.wikipedia.org/wiki/HepaRG
WW   https://lccl.zucmanlab.com/hcc/cellLines/HepaRG
WW   http://triangleresearchlabs.net/products-hepatocytes/nospin-heparg/
WW   https://www.thermofisher.com/order/catalog/product/HPRGC10
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2652.
CC   Characteristics: Can be induced to differentiate into hepatocyte-like cells by exposure to DMSO.
CC   Characteristics: Cell line main applications are sugar and lipid metabolism, physiopathology; drug metabolism and toxicology and viral infection.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Membrane proteome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Secretome proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Anecdotal: The 'RG' in the cell name stands for Rumin and Gripon, the two scientists that were influential in the establishment of this cell line.
CC   Miscellaneous: This cell line is exclusively produced and controlled by Biopredic International and owned by Inserm. BioPredic sells undifferentiated cell line (HPR101) that can be expanded, passaged, and frozen in-house to prepare a cell bank and differentiated ready-to-use cells (HPR116) that can be used immediately or in a few days after thawing, as a single-use disposable product.
CC   Discontinued: Millipore; C103485; true.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C3099; Hepatocellular carcinoma
DI   ORDO; Orphanet_88673; Hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 30
//
RX   Patent=US7456018;
RA   Gripon P., Guguen-Guillouzo C., Trepo C., Rumin S.;
RT   "Human hepatoma lines, methods for obtaining same and uses thereof.";
RL   Patent number US7456018, 25-Nov-2008.
//
RX   PubMed=12432097; DOI=10.1073/pnas.232137699;
RA   Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I.,
RA   Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C.;
RT   "Infection of a human hepatoma cell line by hepatitis B virus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:15655-15660(2002).
//
RX   PubMed=17241619; DOI=10.1016/j.cbi.2006.12.003;
RA   Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F.,
RA   Guguen-Guillouzo C.;
RT   "The human hepatoma HepaRG cells: a highly differentiated model for
RT   studies of liver metabolism and toxicity of xenobiotics.";
RL   Chem. Biol. Interact. 168:66-73(2007).
//
RX   PubMed=17393521; DOI=10.1002/hep.21536;
RA   Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B.,
RA   Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A.;
RT   "Transdifferentiation of hepatocyte-like cells from the human hepatoma
RT   HepaRG cell line through bipotent progenitor.";
RL   Hepatology 45:957-967(2007).
//
RX   PubMed=20228232; DOI=10.1124/dmd.109.031831;
RA   Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.;
RT   "A comparison of whole genome gene expression profiles of HepaRG cells
RT   and HepG2 cells to primary human hepatocytes and human liver
RT   tissues.";
RL   Drug Metab. Dispos. 38:988-994(2010).
//
RX   PubMed=20645056; DOI=10.1007/978-1-60761-688-7_13;
RA   Marion M.-J., Hantz O., Durantel D.;
RT   "The HepaRG cell line: biological properties and relevance as a tool
RT   for cell biology, drug metabolism, and virology studies.";
RL   Methods Mol. Biol. 640:261-272(2010).
//
RX   PubMed=21414303; DOI=10.1016/j.bcp.2011.03.004;
RA   Ceelen L., De Spiegelaere W., David M., De Craene J., Vinken M.,
RA   Vanhaecke T., Rogiers V.;
RT   "Critical selection of reliable reference genes for gene expression
RT   study in the HepaRG cell line.";
RL   Biochem. Pharmacol. 81:1255-1261(2011).
//
RX   PubMed=22568886; DOI=10.1517/17425255.2012.685159;
RA   Andersson T.B., Kanebratt K.P., Kenna J.G.;
RT   "The HepaRG cell line: a unique in vitro tool for understanding drug
RT   metabolism and toxicology in human.";
RL   Expert Opin. Drug Metab. Toxicol. 8:909-920(2012).
//
RX   PubMed=22594799; DOI=10.3109/13813455.2012.683442;
RA   Huaman Samanez C., Caron S., Briand O., Dehondt H., Duplan I.,
RA   Kuipers F., Hennuyer N., Clavey V., Staels B.;
RT   "The human hepatocyte cell lines IHH and HepaRG: models to study
RT   glucose, lipid and lipoprotein metabolism.";
RL   Arch. Physiol. Biochem. 118:102-111(2012).
//
RX   PubMed=22643240; DOI=10.1016/j.tiv.2012.05.008;
RA   Antherieu S., Chesne C., Li R.-Y., Guguen-Guillouzo C., Guillouzo A.;
RT   "Optimization of the HepaRG cell model for drug metabolism and
RT   toxicity studies.";
RL   Toxicol. In Vitro 26:1278-1285(2012).
//
RX   PubMed=22857383; DOI=10.1186/1477-5956-10-47;
RA   Sokolowska I., Dorobantu C.M., Woods A.G., Macovei A.,
RA   Branza-Nichita N., Darie C.C.;
RT   "Proteomic analysis of plasma membranes isolated from undifferentiated
RT   and differentiated HepaRG cells.";
RL   Proteome Sci. 10:47.1-47.13(2012).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//
RX   PubMed=26160117; DOI=10.1093/toxsci/kfv136;
RA   Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E.,
RA   Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G.,
RA   Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.;
RT   "Comparative proteomic characterization of 4 human liver-derived
RT   single cell culture models reveals significant variation in the
RT   capacity for drug disposition, bioactivation, and detoxication.";
RL   Toxicol. Sci. 147:412-424(2015).
//
RX   PubMed=26694163; DOI=10.1371/journal.pone.0144924;
RA   Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K.,
RA   Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M.,
RA   Giefing M., Jarmuz-Szymczak M.;
RT   "Global miRNA expression profiling identifies miR-1290 as novel
RT   potential oncomiR in laryngeal carcinoma.";
RL   PLoS ONE 10:E0144924-E0144924(2015).
//
RX   PubMed=27027780; DOI=10.1007/s10565-016-9316-2;
RA   Wu Y., Geng X.-C., Wang J.-F., Miao Y.-F., Lu Y.-L., Li B.;
RT   "The HepaRG cell line, a superior in vitro model to L-02, HepG2 and
RT   hiHeps cell lines for assessing drug-induced liver injury.";
RL   Cell Biol. Toxicol. 32:37-59(2016).
//
RX   PubMed=27169750; DOI=10.1038/srep24709;
RA   Sharanek A., Burban A., Burbank M., Le Guevel R., Li R.-Y.,
RA   Guillouzo A., Guguen-Guillouzo C.;
RT   "Rho-kinase/myosin light chain kinase pathway plays a key role in the
RT   impairment of bile canaliculi dynamics induced by cholestatic drugs.";
RL   Sci. Rep. 6:24709-24709(2016).
//
RX   PubMed=27780834; DOI=10.1124/dmd.116.072603;
RA   van der Mark V.A., de Waart D.R., Shevchenko V., Oude Elferink R.P.J.,
RA   Chamuleau R.A.F.M., Hoekstra R.;
RT   "Stable overexpression of the constitutive androstane receptor reduces
RT   the requirement for culture with dimethyl sulfoxide for high drug
RT   metabolism in HepaRG cells.";
RL   Drug Metab. Dispos. 45:56-67(2017).
//
RX   PubMed=27975304; DOI=10.1007/978-1-4939-6700-1_2;
RA   Ni Y., Urban S.;
RT   "Hepatitis B virus infection of HepaRG cells, HepaRG-hNTCP cells, and
RT   primary human hepatocytes.";
RL   Methods Mol. Biol. 1540:15-25(2017).
//
RX   PubMed=28904299; DOI=10.2131/jts.42.641;
RA   Tomida T., Ishimura M., Iwaki M.;
RT   "A cell-based assay using HepaRG cells for predicting drug-induced
RT   phospholipidosis.";
RL   J. Toxicol. Sci. 42:641-650(2017).
//
RX   PubMed=30795634; DOI=10.3390/cells8020192;
RA   Tascher G., Burban A., Camus S., Plumel M.I., Chanon S., Le Guevel R.,
RA   Shevchenko V., Van Dorsselaer A., Lefai E., Guguen-Guillouzo C.,
RA   Bertile F.;
RT   "In-depth proteome analysis highlights HepaRG cells as a versatile
RT   cell system surrogate for primary human hepatocytes.";
RL   Cells 8:192.1-192.25(2019).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=33441761; DOI=10.1038/s41598-020-79952-1;
RA   Heintze T., Klein K., Hofmann U., Zanger U.M.;
RT   "Differential effects on human cytochromes P450 by CRISPR/Cas9-induced
RT   genetic knockout of cytochrome P450 reductase and cytochrome b5 in
RT   HepaRG cells.";
RL   Sci. Rep. 11:1000-1000(2021).
//